Genetic testing cost effective for newly diagnosed GIST

September 28, 2020

Because gastrointestinal stromal tumors (GIST) are sensitive to the targeted small molecule therapy imatinib, oncologists tend to treat all patients with metastatic GIST with this drug. However, because this rare type of cancer is caused by different genetic mutations, imatinib does not help all patients equally.

To determine whose cancer may be most responsive, the National Comprehensive Cancer Network suggests that patients undergo genetic testing to identify each individuals' tumor mutations. And yet, only 30 percent of patients have genetic testing at the time of diagnosis, likely due to concerns over cost and utility of testing, said Jason Sicklick, MD, professor of surgery in the Division of Surgical Oncology at University of California San Diego School of Medicine.

"We recommend that all patients with a new diagnosis of metastatic GIST undergo genetic testing prior to the initiation of first-line chemotherapy," said Sicklick, surgical oncologist and co-leader of the Sarcoma Disease Team at Moores Cancer Center at UC San Diego Health. "In doing so, those who are unlikely to benefit from imatinib can be given a treatment better suited for their individual tumor."

In a paper published online on September 29, 2020 in the journal JAMA Network Open, Sicklick and colleagues reported that genetic testing is cost-effective and beneficial for newly diagnosed patients with metastatic GIST, a type of soft tissue sarcoma that develops in specialized nerve cells in the wall of the digestive system, most often occurring in the stomach or small intestine.

The team developed a model to compare the cost effectiveness of targeted gene testing and personalized therapy to patients with metastatic GIST who were prescribed imatinib (marketed as Gleevec). Data analyses were conducted October 2019 to January 2020.

"Genetic testing is cost-effective as it allows clinicians to prescribe chemotherapy in a tumor-specific manner. Patients who would not benefit from imatinib, because of primary tumor resistance, are given alternative therapy," said first author Sudeep Banerjee, MD, who did the research while in the Sicklick lab at Moores Cancer Center and who is now chief resident at David Geffen Medical School at UCLA. "Avoiding ineffective treatment and reduced rates of disease progression are the reasons why genetic testing is cost-effective."

Although the most common sarcoma, GIST is rare with an estimated annual incidence of 6.8 cases per million people in the United States. Eventually this cancer becomes highly resistant to existing drug therapies.

Clinicians fight the growth with progressively aggressive drugs, the downside being that each line of therapy has diminishing effectiveness and higher toxicity for patients. More than 95 percent of patients eventually succumb to drug-resistant GIST, underscoring the importance of starting patients on the most effective available drug not only because it is most cost-effective, but crucial for maintaining and improving quality of life in these patients, said Sicklick, co-corresponding author on the paper.

"The treatment of cancer is becoming an increasingly personalized process," said Banerjee. "There is a rapidly expanding body of research around gene-specific and even mutation-specific therapies that can be effective independent of the site of origin of a given tumor. Genetic testing provides the necessary information for patients to potentially benefit from those novel therapies."
Co-authors include: Abhishek Kumar, Nicole Lopez, Beiqun Zhao, Chih-Min Tang, Mayra Yebra, Hyunho Yoon and James D. Murphy, all of UC San Diego.

Disclosures: Sicklick has research funding from Novartis Pharmaceuticals, Amgen Pharmaceuticals and Foundation Medicine. He serves or served as consultant to Grand Rounds, Loxo Oncology and Deciphera. Sicklick also serves as a speaker for La-Hoffman Roche. Murphy receives consulting fees from the Boston Consulting Group and has equity interest in Sympto Health. Kumar has served as a consultant to Sympto Health.

University of California - San Diego

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to